A Phase 2 interventional study of Exaluren in Alport Syndrome, X-Linked and Alport Syndrome, Autosomal Recessive, sponsored by Eloxx Pharmaceuticals, Inc.. Recruiting at 11 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutations in COL4A3/4/5 genes.
Targeted 24 patients aged 12 and older will be enrolled in the trial.
The study will be comprised of the following periods for each participant:
38 studies on the registry are indexed under Nephritis, Hereditary; 14 are open to participants now.
This study's planned enrollment of 24 is below the median of 50 across 21 interventional studies indexed under Nephritis, Hereditary.
Browse Nephritis, Hereditary studies →Eloxx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Sep 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Exaluren
Drug: Exaluren
Exaluren is a synthetic Eukaryotic Ribosome Selective Glycoside (ERSG)
The change in the degree of podocyte foot process effacement
Measured in kidney biopsies by the change in the Filtration Slit Density (FSD)
Time frame: Baseline to Week 16
The change in the degree of podocyte foot process effacement
Measured in kidney biopsies by the change in the Filtration Slit Density (FSD)
Time frame: Baseline to Week 32
The percentage change in Urine Protein Creatinine Ratio (UPCR)
Calculated from geometric mean of 3 consecutive days of first void urine collection
Time frame: Baseline to Week 16
The percentage change in Urine Protein Creatinine Ratio (UPCR)
Calculated from geometric mean of 3 consecutive days of first void urine collection
Time frame: Baseline to Week 32
The percentage change in estimated Glomerular Filtration Rate (eGFR)
Change in eGFR level
Time frame: Baseline to Week 16 and Week 32
The change in the degree of podocyte foot process effacement
Measured by the change in Foot Process Width (FPW)
Time frame: Baseline to Week 16 and Week 32
The change in collagen expression
Measured by structural changes
Time frame: Baseline to Week 16 and Week 32
Evaluate the safety and tolerability of Exaluren
The incidence and characteristics of adverse events (AEs)
Time frame: Screening to End of Study (Week 36)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ELX-02
Eloxx Pharmaceuticals, Inc.